Detalles de la búsqueda
1.
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Ann Neurol
; 91(6): 782-795, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35289960
2.
Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma.
Clin Exp Allergy
; 51(4): 546-555, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33217063
3.
No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities.
Ann Allergy Asthma Immunol
; 126(6): 666-673, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33465457
4.
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies.
Ann Clin Transl Neurol
; 9(10): 1643-1659, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36165097
5.
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.
Mult Scler Relat Disord
; 46: 102454, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33045496
6.
Similar response to omalizumab in children with allergic asthma from different racial backgrounds.
J Allergy Clin Immunol Pract
; 11(9): 2911-2913, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37088376
Resultados
1 -
6
de 6
1
Próxima >
>>